Sagimet Biosciences Inc. (NASDAQ: SGMT) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT SAGIMET BIOSCIENCES INC.

Sagimet Biosciences Inc. (NASDAQ: SGMT)
Listen to this Section


$6.94
+0.0800 ( +1.17% ) 212.2K

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Clinical Trial Pipeline Stages


Drug Name Stage
Denifanstat w/ BevacizumabDetailsGlioblastoma Phase 3
Denifanstat (ASC40)DetailsAcne Phase 3
DenifanstatDetailsNon-alcoholic steatohepatitis Phase 3
DenifanstatDetailsLiver disease Phase 1

Market Data


Open $6.94
Previous Close $6.86
Volume 212.2K
Market Cap $423.62M
Day Range $6.83 - $7.25
52 Week Range $3.83 - $11.41
Shares Outstanding 61.75M
Change % +1.17%
Net Change ▲ 0.0800
Insider Ownership -0.02%
Exchange NASDAQ
SectorHealthcare
Industry
IPO Year2023
CountryUnited States
UnderwriterGoldman Sachs, TD Cowen, Piper Sandler, Citizens JMP, more

Insider Ownership Transactions

Total Amount Purchased: -6,468,882.00

Date Type Amount Purchased Purchaser
2024-06-07 Sale -9279.00 Hoelscher Paul W.
2024-05-08 Sale -587181.00 Chauche Thierry
2024-04-03 Sale -73014.00 Walbert Timothy P
2024-04-03 Sale -73014.00 Hoelscher Paul W.
2024-03-28 Buy 12100.00 Happel David
2024-01-31 Sale -850000.00 NEW ENTERPRISE ASSOCIATES 13 LP
2024-01-31 Sale -850000.00 SANDELL SCOTT D
2024-01-31 Sale -850000.00 BASKETT FOREST
2024-01-31 Sale -850000.00 NEA Partners 13, Limited Partnership
2024-01-31 Sale -850000.00 KERINS PATRICK J

SEC Filings


Form Type Description Pages Date
schedule Other 1 Nov 14, 2025
8-k 8K-related 66 Nov 13, 2025
10-q Quarterly Reports 55 Nov 13, 2025
4 Insider transactions 1 Nov 06, 2025
8-k 8K-related 64 Oct 23, 2025
8-k 8K-related 13 Aug 22, 2025
8-k 8K-related 15 Aug 14, 2025
10-q Quarterly Reports 62 Aug 13, 2025
8-k 8K-related 65 Aug 13, 2025
4 Insider transactions 1 Jul 23, 2025

Latest News


× Before browsing our site, please accept our cookies policy